XAV-19

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
XAV-19
Accession Number
DB15895
Description

XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses1,2. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-21,2. The therapy offers three beneficial effects: the ability to neutralize the virus, reduce inflammatory responses, and the absence of aggravating reactions following treatment3. Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients1,2. As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384).

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • XAV-19

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Xenothera Innovative Therapy [Link]
  2. News on XAV-19 [Link]
  3. LFB Announcement [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentCoronavirus (SARS-CoV) / Coronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 03, 2020 17:40 / Updated on October 04, 2020 11:46